A Phase I, Prospective, Open-Label, Comparison Study of Lymphoseek and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Cancer of the the Endometrium Who Are Undergoing Lymph Node Dissection
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions
- 06 Jun 2017 Planned End Date changed from 1 Dec 2016 to 1 Nov 2017.
- 06 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2017.
- 11 May 2016 Status changed from not yet recruiting to recruiting.